Abstract #0234

Serial 3D H-1 MRSI of Patients with Newly Diagnosed GBM being Treated with Radiation, Temozolomide, Erlotinib and Bevacizumab

Sarah Nelson¹, Yan Li¹, Janine Lupo¹, Marram Olson¹, Jason Crane¹, Annette Molinaro², Ritu Roy³, Soonmee Cha¹, and Susan Chang²

¹Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, ²Neurological Surgery, University of California, San Francisco, San Francisco, CA, United States, ³Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, United States

Patients with newly diagnosed GBM are typically treated with a combination of radiation and temozolomide in conjunction with a variety of investigational agents. Assessing the effectiveness of such therapies is complicated by differences in their mechanisms of action that lead to ambiguities in the interpretation of conventional anatomic images and difficulties in assessing the spatial extent of tumor. The results of this study demonstrate that integrating 3D lactate edited H-1 MRSI into routine MR examinations and applying quantitative analysis methods allows for the objective evaluation of changes in tumor burden and the early assessment of outcome.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.